Cytos Biotechnolgy AG has completed a major portion of a planned CHF 37 million (€30.8 million) equity and debt financing that will give it the resources to conduct a global, multi-centre Phase 2b study of its lead asthma product, CYT003.
GlaxoSmithKline Plc has announced an agreement to fully acquire Cellzome, a specialist in proteomics technology, for £61 million in cash. GSK currently owns 19.98% of the company which is based in Cambridge, UK and Heidelberg, Germany.
H. Lundbeck A/S said that top-line results from three recently completed Phase 3 trials of its investigational drug for major depressive disorder, Lu AA21004, showed statistically significant reductions in depression symptoms in patients.
Intercell AG has completed a private placement of its shares, raising €15.2 million from the institutional investor BB Biotech, from Novartis, and from a number of other unidentified healthcare investors. The shares were placed at €2.30 per share.
F-Star GmbH, an antibody discovery company, has changed its top management and expanded its operations in Cambridge, UK in preparation for the advance of its bispecific antibody platform to the clinic. CEO Kevin FitzGerald is stepping down.
Evotec AG, which provides discovery services for biopharma companies, reported a 33% increase in revenue for the first 2012 quarter to € 20.1 million but incurred an operating loss of €1.3 million on higher investment in new services and infrastructure.
NicOx SA, which is seeking to build an eye-care business after its non-steroidal anti-inflammatory drug for osteoarthritis failed to get regulatory approval, had a profit in the first 2012 quarter due to a milestone from its ophthalmology platform.
An advisory panel of the US Food and Drug Administration has recommended that the agency approve tofacitinib, a JAK inhibitor which has been developed to treat rheumatoid arthritis. A formal decision is expected in August, according to Pfizer.
Evotec AG and 4-Antibody AG have entered into a strategic collaboration to offer an integrated discovery and development service for companies that are developing antibody therapeutics. Financial terms were not disclosed.
GlaxoSmithKline Plc said that it will take its $13 per share cash offer for Human Genome Sciences Inc directly to shareholders and will not participate in that company’s strategic review. The unsolicited bid is valued at about $2.6 billion.